Huge IRR makes Corella’s Tampu project stand out from the crowd
Corella Resources has unleashed a monstrous scoping study highlighting two highly attractive development scenarios for its Tampu alumina project in WA.
Corella Resources has unleashed a monstrous scoping study highlighting two highly attractive development scenarios for its Tampu alumina project in WA.
October wasn’t hugely strong for junior resource companies, but a few muscled up big time and are entering November looking pretty buff.
As lithium prices slump and a gloomy EV demand outlook emerges, many are bearish on battery metals. But two industry leaders beg to differ.
Alvo Minerals has ridden good news about its Brazilian Bluebush project to a 28 per cent gain for the day. Here’s your ASX resources wrap.
Island Pharmaceuticals aims to guard against mosquito-borne diseases – and now it has more protection itself, with a key patent granted. Get your health news here.
Guru Bernard Marr has predicted the factors that will drive the healthcare sector in 2024. But no need to wait – these ASX stocks are already in high gear.
MGC Pharmaceuticals has secured almost $US8 million in a capital raise to support its business plan, including its focus on FDA IND applications for CimetrA and CannEpil.
Melodiol Global Health subsidiary Mernova Medicinal achieved record revenue of nearly $900k in October with purchase orders over $600k already for November.
With traditional energy sources hit by volatility, these ASX resource players are embracing renewables to save money and help clean up the industry’s image.
The world is on course for a swing towards green steel, and that means higher-grade ore. These ASX stocks are helping drive that transition.
One of 2023’s best performing gold miners – Cambodia-focused Emerald Resources – has crystallised an outsized gain this year to charge into the ASX 200.
Pharmaceutical manufacturer IDT Australia has surged on strong results. Meanwhile, Paradigm Biopharma emerged from a trading halt, only to plummet.
The canny investor keeps an eye on drilling programs, given it’s said that resource explorers live or die by the drill bit. These are set to take centre stage.
Soft tissue repair company Aroa Biosurgery is focused on building its product offering, gaining a foothold in key markets, and transitioning to a high-profitability business.
The vast promise of mRNA vaccines is limited by the spectre of inflammatory reactions. But an ASX firm is tackling that issue – and one of the most deadly cancers.
In the race to satisfy the EV market’s accelerating need for manganese, these ASX explorers are heading in opposite directions.
Nickel Industries says Western vehicle makers are starting to realise they’re going to need Indonesian supply, despite the protestations of its peers.
Copper, lithium and REEs hunter Encounter Resources has lived up to its name – finding niobium-REE carbonatites in WA. Here’s your resources wrap.
A widely anticipated scoping study shows Lithium Energy’s 3.3Mt Solaroz lithium brine project will take just 2-2.5 years to pay back development costs, once in production.
Chimeric Therapeutics made a huge surge after the US Food and Drug Administration threw its support behind a new cancer-fighting drug.
Samples from the 560m-long Warhawk pegmatite at James Bay Minerals’ Aero tenure have returned lithium concentrations containing spodumene crystals, confirming its prospectivity.
Morningstar says property group Abacus faces some headwinds, but still rates it a Buy, with a ‘fair value’ 82 per cent higher than its current price.
It’s not quite two years old, but with a gold resource of more than a million ounces, this miner is no toddler. And it’s caught the eye of columnist Barry FitzGerald.
Amplia Theapeutics’ treatment for pancreatic cancer has taken a step forward, with encouraging results from a key trial. Get the latest health news here.
A geological wonder known as the Ida Fault has incited a new wave of lithium pegging excitement. But one digger is in the area looking for other kinds of battery metals.
Leading Australian crypto exchanges have cautiously backed new plans to regulate the industry, but warn that the nation is already falling behind.
A leading investment fund says the biotech sector is poised for a big upswing … but to cash in, Australian companies and investors must change their ways.
News a Bitcoin spot ETF had been approved caused a stir in the crypto zoo. The report was later debunked, but BTC has retained some of the gains it generated.
PPK Group’s share price surged more than 41 per cent after it slashed the price of an ‘incredible’ material used to make a fibre 100 times stronger than steel.
Alvo Minerals could find itself centre stage in the quest to break China’s rare earths stranglehold, with what looks like a rich ionic clay deposit being investigated.
St George Mining has secured a $3 million strategic joint venture with global lithium-ion battery producer Amperex Technology Limited to fund lithium exploration in WA.
Bailador Technology Investments says the ASX’s only pureplay, tech-driven language service provider, Straker Translations, is well positioned to ride growth tailwinds from AI.
Broker Canaccord Genuity is bullish about a tech-based parking management provider, while MA Moelis likes the look of a mining industry software firm.
Tech innovations are revolutionising mineral processing, unlocking vast riches in previously neglected resources … with these ASX stocks leading the way.
A 2km long chargeability anomaly has indicated Titan Minerals’ Copper Ridge and Meseta prospects at the Linderos project are connected as one large porphyry system.
Under-the-radar stock Jindalee Resources is raising $5.5 million to advance exploration and development at the US’s biggest lithium deposit.
Digital health solution provider Global Health rose more than 6 per cent on Monday after announcing a strategic reseller agreement with Fujitsu Australia.
Maximus has cashed-up partners, inking huge deals with Korean government agency KOMIR and battery maker LG Energy over the Lefroy lithium project.
New extraction processes promise to produce cheaper, higher-quality and more environmentally friendly lithium. These ASX stocks are at the cutting edge.
Momentum trading can supercharge a portfolio, but first the investor has to identify stocks in top gear. Here are three main signals to look out for.
EZZ Life Science will sell 10 of its most popular products on Chemist Warehouse’s new online marketplace, expanding its omnichannel distribution strategy.
Tungsten is the original critical metal, says columnist Barry FitzGerald. So he’s excited by a project that could double an ASX junior’s share price.
War has a devastating, often ongoing, effect on those caught in its chaos. But healing of the financial market tends to be fast, says Tim Boreham.
Australian approvals for medical cannabis through an Authorised Prescriber for the first half of this year were 120 per cent up on the same time in 2022.
The Secret Broker has no love of war, but knows a bit about tactical manoeuvres. Some of it he learnt from the curious case of a bishop and a rubbery stock.
Africa, blessed with a bounty of critical mineral resources, needs to become more than just a raw material exporter to really benefit. These ASX stocks are lending a hand.
Morgans says high interest rates have forced Aussie fintechs to finetune – and now they look set to bounce back strongly as the game changes.
Small (and tiny) stocks have been dumped aggressively of late, magnifying opportunities to find oversold, high-quality microcaps, says Perpetual.
Bitcoin’s been spurned again by CNBC’s Jim Cramer. But a hedge fund legend is feeling the love, saying BTC and gold look good in troubling times.
Melodiol Global Health’s psychedelics subsidiary Halucenex Life Sciences has achieved encouraging results in a clinical trial of psilocybin use for treatment-resistant PTSD.
Original URL: https://www.heraldsun.com.au/business/stockhead/page/52